FDA inspection
Novartis Singapore Pharmaceutical Manufacturing Pte.: FDA inspection ending Mar 3, 2023
FDA inspection 1202885 · No Action Indicated (NAI) · Singapore
Key facts
| Inspection ID | 1202885 |
|---|---|
| Firm | Novartis Singapore Pharmaceutical Manufacturing Pte. |
| FEI number | 3012958979 |
| Address | 8 Tuas Bay Lane |
| City | Singapore |
| Country | Singapore |
| Fiscal year | 2023 |
| Inspection end date | Mar 3, 2023 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data